Inclusion Criteria:

- Written informed consent has been obtained prior to surgical tumour resection and
prior to the performance of any other protocol-specific procedures.

- At least 18 years of age at the time of resection.

- Pathologically proven, surgically staged squamous or non-squamous IB, IIA or IIB
NSCLC, and complete surgical resection.

- The operative technique for resection of the patient's tumour involves at least a
lobectomy or a sleeve lobectomy, conforming to all of the following criteria:

1. Removal of all gross disease with negative resection margins, by lobectomy,
sleeve resection, bilobectomy or pneumonectomy, based on intra-operative
findings.

2. The level of nodal sampling is at least as follows:

Levels 4, 7, 10 in both right upper and right middle lobes Levels 4, 7, 9, 10 in right
lower lobe Levels 5, 6, 7 in left upper lobe Levels 7, 9, 10 in left lower lobe. or at the
maximum defined as systematic radical mediastinal lymphadenectomy: all ipsilateral and
easily accessible lymph-node levels must be removed, independently of the location of the
primary tumour. The level of nodal sampling is as follows: Levels 2, 4, 7, 8, 9, 10 in
right-sided tumours, Levels 5, 6, 7, 8, 9, 10 in left-sided tumours

- Tumour shows expression of MAGE-3 antigen.

- Recovered from surgery for at least 4 weeks and not more than 6 weeks.

- ECOG performance status of ≤ 1 at the time of randomisation.

- Laboratory criteria (all of the following must be fulfilled): adequate bone marrow
reserve, adequate renal function, adequate hepatic function, serum bilirubin within
normal range, negative HIV antibody test, negative HBV antigen test, negative HCV
antibody test.

- (For females): EITHER not of child-bearing potential OR sexually abstinent OR all of
the following: negative urine/serum β-HCG pregnancy test, use of adequate
contraceptive precautions for 30 days before first vaccination. Agree to continue
such precautions for 2 months after completion of the course of vaccination.

Exclusion Criteria:

- Received any anti-cancer specific treatment including radiotherapy, prior to surgery,
unless the treatment was for previous malignancies allowed by the protocol, i.e.,
basal and localised squamous-cell skin carcinoma that has been successfully treated,
or carcinoma in situ of the cervix (see exclusion criterion no. 10).

- Candidate for post-surgery radiation therapy or any kind of anti-cancer-specific
treatment.

- Pregnant/lactating.

- (For female patients of child-bearing potential): not agree to practice an effective
method of contraception.

- Uncontrolled bleeding disorder.

- Autoimmune disease.

- History of anaphylaxis or severe allergic reaction.

- Undergone splenectomy or radiation to the spleen.

- Received a major organ allograft.

- Malignancies at other sites (except (i) basal and localised squamous-cell skin
carcinoma that has been successfully treated, and (ii) carcinoma in situ of the
cervix).

- Concurrent severe medical problems, unrelated to the malignancy, that would
significantly limit full compliance with the study or expose the patient to
unacceptable risk.

- Uncontrolled congestive heart failure or hypertension.

- Unstable heart disease or uncontrolled arrhythmia at the time of enrolment.

- Psychiatric or addictive disorders that may compromise ability to give informed
consent, or to comply with the trial procedures.

- Any evidence of residual tumour after surgery.

- Require concomitant treatment with systemic corticosteroids, or any other
immunosuppressive agents.

- Received chemotherapy, immunotherapy related to NSCLC.

- Need home oxygenation.

- Received any investigational or non-registered drug or vaccine other than the study
vaccine within the 30 days preceding the first dose of study vaccine, or plans to
receive such a drug during the study period.